112.77
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$112.99
Offen:
$113.15
24-Stunden-Volumen:
3.93M
Relative Volume:
0.59
Marktkapitalisierung:
$139.93B
Einnahmen:
$28.80B
Nettoeinkommen (Verlust:
$6.31B
KGV:
22.46
EPS:
5.02
Netto-Cashflow:
$9.37B
1W Leistung:
+0.19%
1M Leistung:
-1.52%
6M Leistung:
-1.72%
1J Leistung:
+42.51%
Gilead Sciences Inc Stock (GILD) Company Profile
Firmenname
Gilead Sciences Inc
Sektor
Telefon
(650) 574-3000
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Vergleichen Sie GILD mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
GILD
Gilead Sciences Inc
|
112.77 | 139.85B | 28.80B | 6.31B | 9.37B | 5.02 |
![]()
LLY
Lilly Eli Co
|
742.91 | 659.07B | 53.26B | 13.80B | -50.20M | 15.30 |
![]()
JNJ
Johnson Johnson
|
178.76 | 428.83B | 90.62B | 22.66B | 18.18B | 9.35 |
![]()
ABBV
Abbvie Inc
|
213.00 | 374.37B | 58.33B | 3.73B | 18.24B | 2.10 |
![]()
NVS
Novartis Ag Adr
|
128.42 | 245.16B | 53.40B | 13.68B | 16.89B | 6.9231 |
![]()
MRK
Merck Co Inc
|
84.05 | 213.51B | 63.43B | 16.42B | 14.72B | 6.49 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-08-19 | Hochstufung | Daiwa Securities | Neutral → Outperform |
2025-08-08 | Hochstufung | Truist | Hold → Buy |
2025-07-25 | Hochstufung | Needham | Hold → Buy |
2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
2025-03-04 | Bestätigt | Oppenheimer | Outperform |
2025-02-18 | Hochstufung | Deutsche Bank | Hold → Buy |
2025-02-13 | Hochstufung | DZ Bank | Hold → Buy |
2025-01-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2024-12-10 | Fortgesetzt | BofA Securities | Buy |
2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
2024-11-14 | Eingeleitet | Citigroup | Buy |
2024-11-08 | Herabstufung | Maxim Group | Buy → Hold |
2024-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
2024-10-17 | Eingeleitet | Bernstein | Outperform |
2024-10-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
2024-07-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
2024-05-01 | Bestätigt | Maxim Group | Buy |
2024-04-24 | Hochstufung | HSBC Securities | Reduce → Hold |
2024-02-22 | Herabstufung | Truist | Buy → Hold |
2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
2023-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
2023-09-06 | Eingeleitet | HSBC Securities | Reduce |
2023-07-24 | Bestätigt | Barclays | Equal Weight |
2023-05-16 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
2023-04-28 | Fortgesetzt | Piper Sandler | Overweight |
2023-01-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
2022-12-13 | Fortgesetzt | BofA Securities | Neutral |
2022-12-09 | Herabstufung | DZ Bank | Buy → Hold |
2022-10-31 | Hochstufung | Barclays | Underweight → Equal Weight |
2022-10-28 | Bestätigt | BMO Capital Markets | Market Perform |
2022-10-28 | Bestätigt | Cowen | Outperform |
2022-10-28 | Bestätigt | JP Morgan | Overweight |
2022-10-28 | Bestätigt | Jefferies | Buy |
2022-10-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
2022-10-28 | Bestätigt | RBC Capital Mkts | Outperform |
2022-10-28 | Hochstufung | Truist | Hold → Buy |
2022-10-28 | Bestätigt | Wells Fargo | Equal Weight |
2022-10-04 | Hochstufung | JP Morgan | Neutral → Overweight |
2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
2022-02-28 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
2022-02-02 | Bestätigt | BMO Capital Markets | Outperform |
2022-02-02 | Bestätigt | BofA Securities | Neutral |
2022-02-02 | Bestätigt | RBC Capital Mkts | Outperform |
2022-02-02 | Bestätigt | Truist | Hold |
2022-02-02 | Bestätigt | Wells Fargo | Equal Weight |
2022-01-28 | Hochstufung | Argus | Hold → Buy |
2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
2021-12-06 | Eingeleitet | Goldman | Neutral |
2021-11-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
2021-11-19 | Fortgesetzt | Piper Sandler | Neutral |
2021-10-20 | Fortgesetzt | Cowen | Outperform |
2021-07-30 | Bestätigt | BMO Capital Markets | Market Perform |
2021-07-30 | Bestätigt | RBC Capital Mkts | Outperform |
2021-04-01 | Hochstufung | Bernstein | Mkt Perform → Outperform |
2021-03-30 | Hochstufung | Redburn | Neutral → Buy |
2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
2020-11-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
2020-10-28 | Eingeleitet | UBS | Neutral |
2020-09-30 | Fortgesetzt | Jefferies | Buy |
2020-09-15 | Hochstufung | Maxim Group | Hold → Buy |
2020-07-31 | Bestätigt | Credit Suisse | Neutral |
2020-07-31 | Bestätigt | Morgan Stanley | Equal-Weight |
2020-07-31 | Bestätigt | Piper Sandler | Overweight |
2020-07-31 | Bestätigt | RBC Capital Mkts | Outperform |
2020-07-31 | Bestätigt | SunTrust | Hold |
2020-07-31 | Bestätigt | Wells Fargo | Equal Weight |
2020-07-20 | Hochstufung | Credit Suisse | Underperform → Neutral |
2020-06-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
2020-05-26 | Hochstufung | SunTrust | Sell → Hold |
2020-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
2020-05-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
2020-05-01 | Herabstufung | SunTrust | Hold → Sell |
2020-04-27 | Herabstufung | UBS | Buy → Neutral |
2020-04-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
2020-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
2020-04-17 | Herabstufung | CFRA | Hold → Sell |
Alle ansehen
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Gilead Partners With US State Department to Distribute Yeztugo to Low-Income Countries - BioSpace
Rx Rundown: Novartis, Gilead Sciences, Remedy Meds and more - Medical Marketing and Media
What to expect from Gilead Sciences Inc. in the next 30 daysMarket Trend Review & Low Risk Profit Maximizing Plans - Newser
Gilead Sciences’ Strategic Expansion in HIV Prevention and Global Access: Assessing Long-Term Investment Potential - AInvest
Gilead Sciences advances HIV prevention with new US partnership - Yahoo Finance
Gilead breaks ground on AI-enabled US manufacturing hub - MarketScreener
Momentum divergence signals in Gilead Sciences Inc. chartWeekly Trade Analysis & Risk Controlled Daily Trade Plans - Newser
Stock Analysis | Gilead Sciences OutlookA Strong Technical Picture with Mixed Analyst Signals - AInvest
What earnings revisions data tells us about Gilead Sciences Inc.Trade Entry Report & Step-by-Step Swing Trade Plans - Newser
Gilead joins U.S. efforts in expanding access to new HIV drug in low-income nations - Seeking Alpha
US plans to bring Gilead HIV drug to market in high-burden HIV countries - Reuters
Gilead partners with PEPFAR to expand HIV prevention access - Investing.com
U.S. to bring Gilead’s HIV drug lenacapavir to high-burden countries - Investing.com
Gilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries - Business Wire
US Plans to Bring Gilead HIV Drug to Market in High-Burden HIV Countries - U.S. News & World Report
Gilead Sciences to Offer Lenacapavir at Cost for Global HIV Prevention - Devdiscourse
Gilead at Wells Fargo Conference: Strategic Growth and Challenges - Investing.com
Gilead Sciences breaks ground on new manufacturing hub - The Pharma Letter
Australia Acute Respiratory Distress Syndrome Market Growth and Company Report 2025-2033 Featuring Silence Therapeutics, Gilead Sciences, Terumo, Getinge, Livanova, Medtronic, Fresenius, Nipro, Pfizer - GlobeNewswire
'I can't wait to see where we go': Gilead launches $32 billion U.S. investment with new Foster City building - The Business Journals
Gilead Breaks Ground on Pharmaceutical Development & Manufacturing Technical Development Center - Contract Pharma
Gilead Sciences describes new Mpro inhibitors for SARS-CoV-2 - BioWorld MedTech
Gilead begins construction of new manufacturing centre in US - World Pharmaceutical Frontiers
Gilead Sciences Launches Choose U Campaign Spotlighting the Inspiring Experiences of People Living with HIV - Business Wire
Gilead, Amgen kick off facility investments in US - pharmaphorum
Gilead Sciences Launches Choose U™ Campaign Spotlighting the Inspiring Experiences of People Living with HIV - Bakersfield.com
Gilead unveils new California manufacturing site, part of $32B US investment - FirstWord Pharma
Gilead Sciences Breaks Ground on New Manufacturing Hub, a Cornerstone of Its U.S. Growth and Innovation Strategy - BioSpace
Is Gilead Sciences Stock Underperforming the Nasdaq? - MSN
Is Gilead Sciences Stock Underperforming The Nasdaq? - Barchart.com
GILD Stock Quote Price and Forecast - CNN
Gilead breaks ground on AI-enabled biopharma hub at Foster City headquarters - KRON4
Gilead starts building manufacturing hub under $32 billion planned US investments - Reuters
Gilead Sciences’ Strategic Position in the Evolving Biopharma Landscape - AInvest
Gilead breaks ground on Foster City manufacturing hub as $32B US investment plan plays out - Fierce Pharma
Gilead at Cantor Global Healthcare Conference: Strategic Focus on Innovation - Investing.com
Gilead Sciences' $32 Billion U.S. Expansion and Its Implications for Biopharma Innovation and Stock Value - AInvest
Gilead Sciences $32B Investment in US Pharma ManufacturingNews and Statistics - IndexBox
Gilead Sciences’ $32 Billion U.S. Expansion and Its Implications for Biopharma Leadership - AInvest
4 Questions on Gilead’s New Technical Development Center with Stacey Ma & Jamie Moore - Gilead Sciences
Gilead Sciences Breaks Ground on New Manufacturing Center at California HQ - MarketScreener
Gilead's $32 Billion US Manufacturing Expansion: A Strategic Catalyst for Long-Term Shareholder Value - AInvest
Gilead breaks ground on manufacturing development site at California HQ - Seeking Alpha
Gilead breaks ground on new Bay Area facility as part of $32 billion investment By Investing.com - Investing.com
Gilead Sciences' $32 Billion U.S. Investment: A Strategic Catalyst for Biopharma Innovation and Shareholder Value - AInvest
Gilead Sciences breaks ground on new manufacturing facility in Foster City - StreetInsider
Intraday pattern recognizer results for Gilead Sciences Inc.Market Risk Analysis & Growth Focused Entry Reports - Newser
Will Gilead Sciences Inc. stock go up soon2025 Dividend Review & Community Consensus Trade Alerts - Newser
How hedge fund analytics apply to Gilead Sciences Inc. stockTake Profit & Growth Oriented Trade Recommendations - Newser
Using RSI to spot recovery in Gilead Sciences Inc.2025 Retail Activity & High Return Stock Watch Alerts - Newser
Gilead's $0.5B Volume Ranks 215th as Q2 Sales Climb and Yeztugo Approval Signals Long-Term Innovation - AInvest
Finanzdaten der Gilead Sciences Inc-Aktie (GILD)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):